Ceribell vs Sanara Medtech
Sanara Medtech is the larger business, with $103m of revenue in fiscal 2025 against $89.1m for Ceribell (1.2 times as much). Ceribell grew faster (36.1% against 19.0%). Sanara Medtech kept more of each dollar of sales as profit: a net margin of -36.4% against -60.0%. Ceribell carries less debt relative to equity (12.8% against 790.2%).
| Latest fiscal year | CeribellCBLL, 2025 | Sanara MedtechSMTI, 2025 |
|---|---|---|
| Revenue | $89.1m | $103m |
| Revenue growth | 36.1% | 19.0% |
| Net income | −$53.4m | −$37.6m |
| Operating margin | -65.6% | 7.1% |
| Net margin | -60.0% | -36.4% |
| Return on equity | -30.8% | -165.7% |
| Free cash flow | −$41.6m | $2.2m |
| Cash | $40.5m | $16.6m |
| Total debt | $19.8m | $46.9m |
| Debt to equity | 12.8% | 790.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 327 | 108 |
| Market value | $1.09bn | $295m |
| Price vs our value range | — | — |
| Moat score | — | 34 (Weak) |
| Insider trades, 12 months | 0 buys, 100 sales | 0 buys, 0 sales |